PERPHENAZINE 8 MG
PERPHENAZINE : 8 MG · DIN 00335118 · AA PHARMA INC
Health Canada status: MARKETED
What is PERPHENAZINE?
PERPHENAZINE 8 MG contains PERPHENAZINE : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 00335118, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Oct-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PERPHENAZINE used for?
Management of manifestations of psychotic disorders. Controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00335118 |
|---|---|
| Brand name | PERPHENAZINE |
| Generic / active ingredient | PERPHENAZINE : 8 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 8 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AB03 PERPHENAZINE |
| AHFS class | 28:16.08.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Oct-2010 |
| Original market date | 1976-12-31 00:00:00 |
How is it administered?
Psychotic disorders: 4-16 mg 2-4 times daily. Nausea/vomiting: 8-16 mg daily in divided doses. Use lowest effective dose. Max 24 mg/day for ambulatory patients.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Available in bottles of 100.
Contraindications
Hypersensitivity; circulatory collapse; comatose/depressed states; blood dyscrasias; bone marrow depression; liver damage; renal insufficiency; pheochromocytoma; severe cardiovascular disorders.
Warnings and precautions
Increased mortality in elderly with dementia. Risk of Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, QT prolongation, and blood dyscrasias. May impair driving/machinery operation.
Is PERPHENAZINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by AA PHARMA INC, last seen 12 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05AB03 PERPHENAZINE. 4 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PERPHENAZINE | 16 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00335096 |
| PERPHENAZINE | 2 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00335134 |
| PERPHENAZINE | 4 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00335126 |
| PERPHENAZINE 16 TAB | 16 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00563722 |
| PERPHENAZINE 2 TAB 2MG | 2 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00563757 |
| PERPHENAZINE 8 TAB 8MG | 8 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00563730 |
| PERPHENAZINE TAB 2MG | 2 MG | TABLET | D.C. LABS LIMITED | CANCELLED POST MARKET | DIN 00456039 |
| PERPHENAZINE TAB 4MG | 4 MG | TABLET | D.C. LABS LIMITED | CANCELLED POST MARKET | DIN 00456047 |
| PERPHENAZINE TAB 4MG | 4 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00563749 |
| PHENAZINE 16 TAB | 16 MG | TABLET | ICN CANADA LTD. | CANCELLED POST MARKET | DIN 00294802 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.